ClinicalTrials.gg
CompletedNCT07246902MOVEUpdated Sep 18, 2026

Mobilization and Outcomes After Venous Closure

An observational study in Venous Vascular Closure and Electrophysiology Study, sponsored by Cordis US Corp.. Completed at 9 sites in United States. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Cordis US Corp. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
339
Sex
All
01

Study summary

The primary objective of this post-market registry is to collect real-world outcomes and evaluate usage practice of MYNX CONTROL™ VENOUS (MCV) Vascular Closure Device (VCD) 6F-12F in sealing femoral venous access sites in patients who have undergone endovascular procedures in a real-world setting.

Read the detailed description

The study is a single-arm, prospective, multi-center, observational, real-world registry of venous access site closures utilizing MYNX CONTROL™ VENOUS VCD 6F-12F following endovascular procedures. The study will enroll approximately 300 subjects in approximately 15 study sites in the United States.

02

Conditions studied

  • Venous Vascular Closure
  • Electrophysiology Study

Keywords

  • Electrophysiology Study
  • Venous closure
  • Venous access closure
  • Vascular access closure
  • Venous Vascular Closure
  • Vascular closure device
  • MYNX CONTROL VENOUS
  • MOVE Registry
  • MOVE
  • Cardiac Catheterization
  • MYNX
03

In context

Lead sponsor

Cordis US Corp. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study includes patients who undergo catheter-based procedures utilizing 6F to 12F inner diameter procedural sheaths, with single or multiple venous access sites in one or both limbs, and have their venous access site(s) closed with MYNX CONTROL™ VENOUS VCD 6F-12F per IFU.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide and to complete a follow-up visit at 14 ± 7 days post-procedure.
  2. Individuals undergoing catheter-based procedures utilizing 6F to 12F inner diameter procedural sheaths, with single or multiple venous access sites in one or both limbs.
  3. Individuals who are candidates to have their venous access site(s) closed with MYNX CONTROL™ VENOUS VCD 6F-12F per IFU.
  4. At the time of enrollment, the Investigator deems the subject a candidate for same-day discharge (SDD) per standard of care (no procedure related events/complications e.g., no new pericardial effusion, post-procedure diuresis not needed, etc.).

Exclusion criteria

Exclusion Criteria

  1. Presence of bruit, palpable aneurysm, significant candida or groin infection.
  2. Prior to closure, presence of hematoma in the accessed limb.
  3. Currently involved in any other clinical trial that may interfere with the outcomes of this study as determined by the Investigator.
  4. Planned use of other closure devices or techniques other than MYNX CONTROL™ VENOUS VCD 6F-12F.
  5. \<12 months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
339 participants (actual)
Target follow-up
14 Days
Patient registry
Yes

Groups and cohorts

  • MCV VCD Treatment

    Subjects who undergo catheter-based procedures utilizing 6F to 12F inner diameter procedural sheaths, with single or multiple venous access sites in one or both limbs, and have their venous access site(s) closed with MYNX CONTROL™ VENOUS VCD 6F-12F per IFU.

    Device: MYNX CONTROLTM VENOUS Vascular Closure Device

Interventions

  • DeviceMYNX CONTROLTM VENOUS Vascular Closure Device

    The MYNX CONTROLTM VENOUS (MCV) Vascular Closure Device (VCD) 6F-12F is indicated for use to seal femoral venous access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing 6F to 12F procedural sheaths, with single or multiple access sites in one or both limbs. MCV VCD is designed to achieve femoral vein hemostasis via delivery of the GRIP TECHNOLOGY™ sealant (an extravascular, water-soluble synthetic hydrogel), using a balloon catheter in conjunction with a standard procedural sheath. The sealant is made of a polyethylene glycol (PEG) material which expands upon contact with subcutaneous fluids to seal the venotomy and is resorbed by the body within 30 days. The MCV VCD is supplied with a 10ml locking syringe used for balloon inflation and deflation. The catheter shaft has a silicone lubricant to facilitate insertion and withdrawal into compatible sheaths.

06

What researchers measure

Primary outcomes

  1. Rate of patients with same day discharge (SDD) and without subsequent hospitalization/intervention for access-site complications

    Rate of patients who successfully received a study device at all access sites and had SDD without subsequent hospitalization/intervention for access-site complications either same day post-discharge or the next day

    Time frame: From time of index procedure through end of following day (within 48 hours)

  2. Rate of access-site complications

    Rate of access-site complications, assessed per standard of care, through 14 days post-procedure, including: * Access Site-Related Hematoma \> 6 cm documented by ultrasound * Local Access Site Infection confirmed by culture and sensitivity, treated with intramuscular or oral antibiotics * Allergic Reaction * Access site-related bleeding requiring transfusion, surgical intervention, or rehospitalization * Pulmonary embolism requiring surgical or endovascular intervention and/or resulting in death, to be confirmed by CT pulmonary angiography, lung ventilation/perfusion scan (VQ scan), or autopsy * Ipsilateral deep vein thrombosis, documented by ultrasound

    Time frame: From time of study device introduction at first access site through 14 days post-procedure

Other outcomes

  1. Time to Ambulation

    Defined as elapsed time (in hours) between removal of the final MCV VCD and when subject stands and walks 20 feet without evidence of rebleeding from any femoral venous access site.

    Time frame: From end of index procedure until time before hospital discharge (usually within ~24 hours of procedure)

  2. Time to Discharge

    Defined as the elapsed time (in minutes) between removal of the final MCV VCD and when the subject is discharged from the hospital, as recorded on the discharge order.

    Time frame: From end of index procedure until time of hospital discharge (usually within ~24 hours of procedure)

  3. Time to Hemostasis

    Defined as elapsed time (in minutes) between removal of each MCV VCD and first observed and confirmed venous hemostasis (per access site analysis).

    Time frame: From time of index procedure until time before hospital discharge (usually within ~24 hours of procedure)

  4. SDD sustained MCV VCD success

    Defined as the proportion of subjects who did not require hospital intervention within 14 days post-procedure due to access site-related complications

    Time frame: From end of index procedure through 14 days post-procedure

  5. Device success evaluated at the end of the procedure

    Defined as the ability to deploy the delivery system and deliver the PEG component to achieve hemostasis at each access site

    Time frame: End of index procedure

  6. Procedural Success

    Defined as the attainment of final hemostasis at all venous access sites without major venous access site closure-related complications through 14 days

    Time frame: From end of index procedure through 14 days post-procedure

  7. Procedural Time

    Defined as time of first sheath insertion until the time of removal of final MCV VCD.

    Time frame: Index procedure

  8. Recovery room time

    Defined as elapsed time (in minutes) between when the subject is transferred to recovery and when the subject is discharged from the hospital, as recorded on the discharge order.

    Time frame: From time of transfer to recovery room post-discharge to time of discharge (usually within ~24 hours of procedure)

  9. Analysis of Cost Effectiveness - Comprehensive summary of clinical outcomes, resource utilization, economic proxies, patients reported outcomes and CPT codes

    An analysis of cost effectiveness will be performed based on a summary of key clinical outcomes, resource utilization, economic proxies, patients reported outcomes and CPT codes

    Time frame: From start time of index procedure through 14 days post-procedure

  10. Incidence of urinary catheter usage

    Number/rate of patients with urinary catheters used during the procedure

    Time frame: From start time of index procedure through end time of index procedure

  11. Incidence of protamine usage

    Incidence of protamine usage during the procedure

    Time frame: From start time of index procedure through end time of index procedure

  12. Medication Usage

    Rate of patients who are administered anti-platelet, anti-coagulant, anti-thrombotic, local anesthetic, protamine or pain medication

    Time frame: From pre-procedure though study exit/follow-up visit (14 +/- 7 days post-procedure)

07

Study locations

9 sites
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • Stanford University School of Medicine
    Palo Alto, California 94304, United States
  • South Denver Cardiology
    Littleton, Colorado 80210, United States
  • AdventHealth Orlando
    Orlando, Florida 32803, United States
  • Glenbrook Hospital
    Glenview, Illinois 60026, United States
  • KC Heart and Rhythm Institute
    Overland Park, Kansas 66211, United States
  • Baptist Health Lexington
    Lexington, Kentucky 40503, United States
  • North Carolina Heart & Vascular Research, LLC
    Raleigh, North Carolina 27607, United States
  • Overlake Medical Center
    Bellevue, Washington 98004, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2025 to primary completion in Aug 2026, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 24, 2025
StartActual
Nov 24, 2025
Primary completionActual
Aug 26, 2026
CompletionActual
Aug 26, 2026
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07246902
Lead sponsor
Cordis US Corp.
Collaborators
NAMSA
Responsible party
Sponsor
First posted
Nov 24, 2025
Start date
Nov 24, 2025
Primary completion
Aug 26, 2026
Completion
Aug 26, 2026
Last update
Sep 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion